Direct 8(a) award, stand-alone, labor-hour (LH) type contract for food and drug administration for oncology center of excellence benefits risk professional services.
Active Definitive Contract Awarded Last action
- Contract number
- 75F40126C00027
- Awardee
-
Aneon Brillient, LLC UEI MS8HMAY331Q5
- Awarding agency
-
Food and Drug Administration
Department of Health and Human Services
- Obligated
- $1,898,236
Award facts
- Opportunity
-
- 75F40126R00015 Solicitation number
- Contract value 100% obligated
- $1,898,235.96 Current and potential, with all options
- Completion date 21% complete
- Current and potential, with all options
- NAICS code
- 541611 Administrative Management and General Management Consulting Services
- PSC
- R699 Support- Administrative: Other
- Set-aside
- 8(a) Sole Source
- Competition
- Not Available for Competition · 1 offer Only One Source
- Pricing
- Labor Hours
- Place of performance
- Silver Spring, MD 20993, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
About this award
The Food and Drug Administration (FDA) awarded an 8(a) sole source, stand-alone labor-hour contract to Aneon Brillient, LLC, a minority-owned, SBA-certified 8(a) joint venture based in Reston, Virginia, for professional services supporting the Oncology Center of Excellence. The contract, with a ceiling value of $1.9M, was awarded on August 12, 2026, and extends through August 11, 2027. Work will be performed in Silver Spring, Maryland. As a small disadvantaged business, Aneon Brillient leverages its 8(a) certification to deliver specialized support services to the FDA across multiple centers and offices, and this contract represents a continuation of the company's focused engagement with the agency's regulatory and scientific operations.
Aneon Brillient has established a robust portfolio of FDA contracts spanning various centers including the Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), and Center for Devices and Radiological Health (CDRH), providing services such as medical and scientific writing, quality assurance, administrative support, and technical staffing. Beyond this direct award, the company holds a significantly larger GSA OASIS+ 8(a) multiple-award indefinite delivery contract with a $999.9B ceiling through April 2030, positioning it to compete for task orders across broader federal agencies. The Oncology Center of Excellence engagement demonstrates the FDA's confidence in Aneon Brillient's capability to support specialized agency missions through a dedicated labor-hour arrangement.
Quick answers
Who was awarded contract 75F40126C00027?
75F40126C00027 was awarded to Aneon Brillient, LLC by Food and Drug Administration (Department of Health and Human Services) on August 12, 2026.
How much is contract 75F40126C00027 worth?
The government has obligated $1,898,236 on 75F40126C00027.
Was contract 75F40126C00027 competed?
The extent of competition for 75F40126C00027 was not available for competition. The government received 1 offer. It was set aside: 8(a) Sole Source.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award